Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism

Abstract

To provide a mixture, a dissolving solution and a pharmaceutical agent, which contain a thermophilic microorganism to make it possible to regulate a mucous membrane immune system gene cluster and metabolism-related gene clusters of the intestines and the liver. Each of them is prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less. By being administered to the animal, it regulates at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines, and a metabolism-related gene cluster in the liver of the animal. The microorganism includes at least one species of the genus Bacillus, Oceanobacillus, Paenibacillus, Anoxybacillus, Lysinibacillus, Methanopyrus, Geogemma, Pyrolobus, Pyrodictium, Hyperthermus, Pyrococcus, Pyrobaculum, Thermococcus, Aeropyrum, Aquifex, Thermotoga, Thermodesulfobacterium, Thermus, Geobacillus, and Thermomyces.

1 . A mixture or a dissolving solution for regulating at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines and a metabolism-related gene cluster in the liver of an animal by being administered to the animal, prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less, wherein the thermophilic microorganism includes at least one species of the genus  Bacillus, Oceanobacillus, Paenibacillus, Anoxybacillus, Lysinibacillus, Methanopyrus, Geogemma, Pyrolobus, Pyrodictium, Hyperthermus, Pyrococcus, Pyrobaculum, Thermococcus, Aeropyrum, Aquifex, Thermotoga, Thermodesulfobacterium, Thermus, Geobacillus, Thermomyces , and  Clostridium.    
     
     
         2 . The mixture or dissolving solution according to  claim 1 , including thermophilic mixed bacteria BP-1051 as the thermophilic microorganism. 
     
     
         3 . The mixture or dissolving solution according to  claim 1 , including a related species of  Bacillus thermoamylovorans , BP-863, as the thermophilic microorganism, where the BP-863 has an ability to degrade persistent sugar. 
     
     
         4 . The mixture or dissolving solution according to  claim 1 , including thermophilic seed bacteria PTA-1773 as the thermophilic microorganism. 
     
     
         5 . A pharmaceutical agent, comprising:
 a mixture or dissolving product for regulating at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines and a metabolism-related gene cluster in the liver of an animal by being administered to the animal, prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less, wherein the thermophilic microorganism includes at least one species of the genus  Bacillus, Oceanobacillus, Paenibacillus, Anoxybacillus, Lysinibacillus, Methanopyrus, Geogemma, Pyrolobus, Pyrodictium, Hyperthermus, Pyrococcus, Pyrobaculum, Thermococcus, Aeropyrum, Aquifex, Thermotoga, Thermodesulfobacterium, Thermus, Geobacillus, Thermomyces , and  Clostridium.      
     
     
         6 . The agent of  claim 5 , including thermophilic mixed bacteria BP-1051 as the thermophilic microorganism. 
     
     
         7 . The agent of  claim 5 , including a related species of  Bacillus thermoamylovorans, BP -863, as the thermophilic microorganism, where the BP-863 has an ability to degrade persistent sugar. 
     
     
         8 . The agent of  claim 5 , including thermophilic seed bacteria PTA-1773 as the thermophilic microorganism.